Hormonal
GLP-1 receptor agonists (GLP-1RAs) significantly improve liver enzymes (AST, ALT, GGT) and reduce fibrosis scores in patients with MAFLD and T2DM, though they are not recommended as a primary treatment for NASH histology in the absence of diabetes.
If you have type 2 diabetes and fatty liver, GLP-1 medications (like Semaglutide) can significantly improve your liver enzymes and reduce scarring markers. They are recommended by guidelines for this specific group. However, they can cause stomach issues like nausea, which leads many people to stop taking them. Discuss with your doctor if the benefits for your liver and heart outweigh the side effects.
A recent meta-analysis showed improvements in AST... ALT... and GGT... and reduction in FIB-4 score... when compared to placebo favoring use of GLP-1RAs for treatment of MAFLD
Why this rating
Supported by meta-analyses showing biochemical improvements, but long-term histological data is limited.
Source
Management of metabolic-associated fatty liver disease: The diabetology perspective
Mohammad Sadiq Jeeyavudeen et al. · World Journal of Gastroenterology · 2023
DOI 10.3748/wjg.v29.i1.126
More from this paper
- Lifestyle interventions achieving 7-10% body weight loss are effective in resolving nonalcoholic steatohepatitis (NASH) and regressing fibrosis in patients with metabolic-associated fatty liver disease (MAFLD).Good
- Pioglitazone improves NASH histology without worsening fibrosis in patients with T2DM and MAFLD, but its use is limited by side effects including weight gain, fluid retention, and potential bladder cancer risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →